• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在反义寡核苷酸中,在选定位置引入亚甲基膦酸酯核苷间键和 2'-甲基修饰可以增强 RNaseH1 活性 PS-ASO 的性能。

The Combination of Mesyl-Phosphoramidate Inter-Nucleotide Linkages and 2'--Methyl in Selected Positions in the Antisense Oligonucleotide Enhances the Performance of RNaseH1 Active PS-ASOs.

机构信息

Department of Core Antisense Research, Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.

出版信息

Nucleic Acid Ther. 2022 Oct;32(5):401-411. doi: 10.1089/nat.2022.0005. Epub 2022 Jul 20.

DOI:10.1089/nat.2022.0005
PMID:35861704
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9595634/
Abstract

Antisense oligonucleotides (ASOs) that mediate RNA target degradation by RNase H1 are used as drugs to treat various diseases. Previously we found that introduction of a single 2'--methyl (2'-OMe) modification in position 2 of the central deoxynucleotide region of a gapmer phosphorothioate (PS) ASO, in which several residues at the termini are 2'-methoxyethyl, 2' constrained ethyl, or locked nucleic acid, dramatically reduced cytotoxicity with only modest effects on potency. More recently, we demonstrated that replacement of the PS linkage at position 2 or 3 in the gap with a mesyl-phosphoramidate (MsPA) linkage also significantly reduced toxicity without meaningful loss of potency and increased the elimination half-life of the ASOs. In this study, we evaluated the effects of the combination of MsPA linkages and 2'-OMe nucleotides on PS ASO performance. We found that two MsPA modifications at the 5' end of the gap or in the 3'-wing of a Gap 2'-OMe PS ASO substantially increased the activity of ASOs with OMe at position 2 of the gap without altering the safety profile. Such effects were observed with multiple sequences in cells and animals. Thus, the MsPA modification improves the RNase H1 cleavage rate of PS ASOs with a 2'-OMe in the gap, significantly reduces binding of proteins involved in cytotoxicity, and prolongs elimination half-lives.

摘要

反义寡核苷酸 (ASO) 通过 RNase H1 介导 RNA 靶标降解,被用作治疗各种疾病的药物。我们之前发现,在具有末端几个残基为 2'-甲氧基乙氧基、2'-约束乙基或锁核酸的间隔区硫代磷酸酯 (PS) ASO 的中央脱氧核苷酸区域的 2'位置引入单个 2'-甲基 (2'-OMe) 修饰,可在对效力仅有适度影响的情况下大大降低细胞毒性。最近,我们证明在 Gap 中位置 2 或 3 的 PS 键合用甲磺酰基磷酸酰胺 (MsPA) 键合取代也显著降低了毒性,而没有显著降低效力,并增加了 ASO 的消除半衰期。在这项研究中,我们评估了 MsPA 键合和 2'-OMe 核苷酸组合对 PS ASO 性能的影响。我们发现,在 Gap 2'-OMe PS ASO 的 Gap 或 3'-翼的 5' 端的两个 MsPA 修饰,在不改变安全性特征的情况下,大大增加了具有 Gap 中位置 2 的 OMe 的 ASO 的活性。在细胞和动物中观察到了多种序列的这种效应。因此,MsPA 修饰提高了具有 Gap 中 2'-OMe 的 PS ASO 的 RNase H1 切割速率,显著降低了参与细胞毒性的蛋白质的结合,并延长了消除半衰期。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5196/9595634/637fc4d4064c/nat.2022.0005_figure6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5196/9595634/76340ac549bd/nat.2022.0005_figure1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5196/9595634/ea3c4eae1c63/nat.2022.0005_figure2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5196/9595634/70128ad9f2b7/nat.2022.0005_figure3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5196/9595634/5d9c3537c0ba/nat.2022.0005_figure4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5196/9595634/5368a4809ed4/nat.2022.0005_figure5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5196/9595634/637fc4d4064c/nat.2022.0005_figure6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5196/9595634/76340ac549bd/nat.2022.0005_figure1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5196/9595634/ea3c4eae1c63/nat.2022.0005_figure2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5196/9595634/70128ad9f2b7/nat.2022.0005_figure3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5196/9595634/5d9c3537c0ba/nat.2022.0005_figure4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5196/9595634/5368a4809ed4/nat.2022.0005_figure5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5196/9595634/637fc4d4064c/nat.2022.0005_figure6.jpg

相似文献

1
The Combination of Mesyl-Phosphoramidate Inter-Nucleotide Linkages and 2'--Methyl in Selected Positions in the Antisense Oligonucleotide Enhances the Performance of RNaseH1 Active PS-ASOs.在反义寡核苷酸中,在选定位置引入亚甲基膦酸酯核苷间键和 2'-甲基修饰可以增强 RNaseH1 活性 PS-ASO 的性能。
Nucleic Acid Ther. 2022 Oct;32(5):401-411. doi: 10.1089/nat.2022.0005. Epub 2022 Jul 20.
2
Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides.了解控制 DNA 间隙中硫代磷酸酯手性对 gapmer 反义寡核苷酸效力和安全性的影响。
Nucleic Acids Res. 2020 Feb 28;48(4):1691-1700. doi: 10.1093/nar/gkaa031.
3
Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.对 PS-ASO 治疗药物进行化学修饰可降低细胞内蛋白质结合,提高治疗指数。
Nat Biotechnol. 2019 Jun;37(6):640-650. doi: 10.1038/s41587-019-0106-2. Epub 2019 Apr 29.
4
Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.热休克蛋白90(Hsp90)与含有疏水性2'-修饰的硫代磷酸酯寡核苷酸相互作用,并增强反义活性。
Nucleic Acids Res. 2016 May 5;44(8):3892-907. doi: 10.1093/nar/gkw144. Epub 2016 Mar 3.
5
Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides.迈向新一代反义寡核苷酸:甲磺酸酯磷酰胺修饰提高了 Gapmer 反义寡核苷酸的治疗指数和作用持续时间。
Nucleic Acids Res. 2021 Sep 20;49(16):9026-9041. doi: 10.1093/nar/gkab718.
6
NAT10 and DDX21 Proteins Interact with RNase H1 and Affect the Performance of Phosphorothioate Oligonucleotides.NAT10 和 DDX21 蛋白与 RNase H1 相互作用并影响硫代磷酸寡核苷酸的性能。
Nucleic Acid Ther. 2022 Aug;32(4):280-299. doi: 10.1089/nat.2021.0107. Epub 2022 Jul 18.
7
Acute hepatotoxicity of 2' fluoro-modified 5-10-5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins.氟代修饰 5-10-5 间隙寡核苷酸硫代磷酸酯在小鼠中的急性肝毒性与细胞内蛋白结合和 DBHS 蛋白丢失相关。
Nucleic Acids Res. 2018 Mar 16;46(5):2204-2217. doi: 10.1093/nar/gky060.
8
Systematic Analysis of Chemical Modifications of Phosphorothioate Antisense Oligonucleotides that Modulate Their Innate Immune Response.对调节其天然免疫反应的硫代磷酸酯反义寡核苷酸化学修饰的系统分析。
Nucleic Acid Ther. 2023 Apr;33(2):95-107. doi: 10.1089/nat.2022.0067. Epub 2023 Feb 7.
9
Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins.通过调节与细胞蛋白的相互作用,使硫代磷酸酯与烷基膦酸酯键在特定部位进行替换,增强了 gapmer ASO 的治疗谱。
Nucleic Acids Res. 2019 Jun 20;47(11):5465-5479. doi: 10.1093/nar/gkz247.
10
Binding of phosphorothioate oligonucleotides with RNase H1 can cause conformational changes in the protein and alter the interactions of RNase H1 with other proteins.硫代磷酸寡核苷酸与 RNase H1 的结合会导致蛋白质构象发生变化,并改变 RNase H1 与其他蛋白质的相互作用。
Nucleic Acids Res. 2021 Mar 18;49(5):2721-2739. doi: 10.1093/nar/gkab078.

引用本文的文献

1
Chemical Modifications in Nucleic Acid Therapeutics.核酸疗法中的化学修饰
Methods Mol Biol. 2025;2965:57-126. doi: 10.1007/978-1-0716-4742-4_3.
2
Endogenous Ribonucleases: Therapeutic Targeting of the Transcriptome Through Oligonucleotide-Triggered RNA Inactivation.内源性核糖核酸酶:通过寡核苷酸触发的RNA失活对转录组进行治疗靶向
Biomolecules. 2025 Jul 4;15(7):965. doi: 10.3390/biom15070965.
3
Metabolic Stability and Targeted Delivery of Oligonucleotides: Advancing RNA Therapeutics Beyond The Liver.寡核苷酸的代谢稳定性与靶向递送:推动RNA疗法超越肝脏应用。

本文引用的文献

1
Early rRNA processing is a stress-dependent regulatory event whose inhibition maintains nucleolar integrity.早期 rRNA 加工是一种应激依赖的调节事件,其抑制作用可维持核仁的完整性。
Nucleic Acids Res. 2022 Jan 25;50(2):1033-1051. doi: 10.1093/nar/gkab1231.
2
Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides.迈向新一代反义寡核苷酸:甲磺酸酯磷酰胺修饰提高了 Gapmer 反义寡核苷酸的治疗指数和作用持续时间。
Nucleic Acids Res. 2021 Sep 20;49(16):9026-9041. doi: 10.1093/nar/gkab718.
3
Mesyl Phosphoramidate Oligonucleotides as Potential Splice-Switching Agents: Impact of Backbone Structure on Activity and Intracellular Localization.
J Med Chem. 2025 Apr 10;68(7):6870-6896. doi: 10.1021/acs.jmedchem.4c02528. Epub 2025 Jan 8.
4
Discovery and characterization of stereodefined PMO-gapmers targeting tau.靶向tau的立体定向PMO缺口嵌合体的发现与表征
Mol Ther Nucleic Acids. 2024 Nov 28;36(1):102404. doi: 10.1016/j.omtn.2024.102404. eCollection 2025 Mar 11.
5
Evolution of antisense oligonucleotides: navigating nucleic acid chemistry and delivery challenges.反义寡核苷酸的发展:应对核酸化学及递送挑战
Expert Opin Drug Discov. 2025 Jan;20(1):63-80. doi: 10.1080/17460441.2024.2440095. Epub 2024 Dec 17.
6
Amplifying gene expression with RNA-targeted therapeutics.利用 RNA 靶向治疗技术增强基因表达。
Nat Rev Drug Discov. 2023 Jul;22(7):539-561. doi: 10.1038/s41573-023-00704-7. Epub 2023 May 30.
7
Drug Discovery Perspectives of Antisense Oligonucleotides.反义寡核苷酸的药物发现前景
Biomol Ther (Seoul). 2023 May 1;31(3):241-252. doi: 10.4062/biomolther.2023.001. Epub 2023 Mar 2.
8
Antisense oligonucleotide is a promising intervention for liver diseases.反义寡核苷酸是一种很有前景的肝脏疾病干预手段。
Front Pharmacol. 2022 Dec 9;13:1061842. doi: 10.3389/fphar.2022.1061842. eCollection 2022.
9
Towards Personalized Allele-Specific Antisense Oligonucleotide Therapies for Toxic Gain-of-Function Neurodegenerative Diseases.针对功能获得性毒性神经退行性疾病的个性化等位基因特异性反义寡核苷酸疗法
Pharmaceutics. 2022 Aug 16;14(8):1708. doi: 10.3390/pharmaceutics14081708.
甲磺酸磷酰胺寡核苷酸作为潜在的剪接转换剂:主链结构对活性和细胞内定位的影响。
Nucleic Acid Ther. 2021 Jun;31(3):190-200. doi: 10.1089/nat.2020.0860. Epub 2021 May 14.
4
Binding of phosphorothioate oligonucleotides with RNase H1 can cause conformational changes in the protein and alter the interactions of RNase H1 with other proteins.硫代磷酸寡核苷酸与 RNase H1 的结合会导致蛋白质构象发生变化,并改变 RNase H1 与其他蛋白质的相互作用。
Nucleic Acids Res. 2021 Mar 18;49(5):2721-2739. doi: 10.1093/nar/gkab078.
5
Mesyl phosphoramidate backbone modified antisense oligonucleotides targeting miR-21 with enhanced in vivo therapeutic potency.靶向 miR-21 的 Mesyl 膦酰胺酸骨架修饰反义寡核苷酸,具有增强的体内治疗效力。
Proc Natl Acad Sci U S A. 2020 Dec 22;117(51):32370-32379. doi: 10.1073/pnas.2016158117. Epub 2020 Dec 7.
6
Antisense drug discovery and development technology considered in a pharmacological context.从药理学角度考虑的反义药物发现和开发技术。
Biochem Pharmacol. 2021 Jul;189:114196. doi: 10.1016/j.bcp.2020.114196. Epub 2020 Aug 13.
7
Interaction of ASOs with PC4 Is Highly Influenced by the Cellular Environment and ASO Chemistry.反义寡核苷酸(ASO)与PC4的相互作用受到细胞环境和ASO化学性质的高度影响。
J Am Chem Soc. 2020 May 27;142(21):9661-9674. doi: 10.1021/jacs.0c01808. Epub 2020 May 15.
8
Origins of the Increased Affinity of Phosphorothioate-Modified Therapeutic Nucleic Acids for Proteins.硫代磷酸酯修饰的治疗性核酸与蛋白质亲和力增加的起源。
J Am Chem Soc. 2020 Apr 22;142(16):7456-7468. doi: 10.1021/jacs.9b13524. Epub 2020 Apr 10.
9
Kinetic and subcellular analysis of PS-ASO/protein interactions with P54nrb and RNase H1.与 P54nrb 和 RNase H1 的 PS-ASO/蛋白质相互作用的动力学和亚细胞分析。
Nucleic Acids Res. 2019 Nov 18;47(20):10865-10880. doi: 10.1093/nar/gkz771.
10
Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.对 PS-ASO 治疗药物进行化学修饰可降低细胞内蛋白质结合,提高治疗指数。
Nat Biotechnol. 2019 Jun;37(6):640-650. doi: 10.1038/s41587-019-0106-2. Epub 2019 Apr 29.